NO20023894L - Purinderivater - Google Patents
PurinderivaterInfo
- Publication number
- NO20023894L NO20023894L NO20023894A NO20023894A NO20023894L NO 20023894 L NO20023894 L NO 20023894L NO 20023894 A NO20023894 A NO 20023894A NO 20023894 A NO20023894 A NO 20023894A NO 20023894 L NO20023894 L NO 20023894L
- Authority
- NO
- Norway
- Prior art keywords
- purine derivatives
- purine
- derivatives
- Prior art date
Links
- 229940083251 peripheral vasodilators purine derivative Drugs 0.000 title 1
- 125000000561 purinyl group Chemical class N1=C(N=C2N=CNC2=C1)* 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/08—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Crystallography & Structural Chemistry (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Obesity (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0003960.2A GB0003960D0 (en) | 2000-02-18 | 2000-02-18 | Purine derivatives |
| PCT/IB2001/000167 WO2001060835A1 (en) | 2000-02-18 | 2001-02-09 | Purine derivatives |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20023894D0 NO20023894D0 (no) | 2002-08-16 |
| NO20023894L true NO20023894L (no) | 2002-10-01 |
Family
ID=9886026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20023894A NO20023894L (no) | 2000-02-18 | 2002-08-16 | Purinderivater |
Country Status (39)
| Country | Link |
|---|---|
| US (1) | US6525032B2 (no) |
| EP (1) | EP1255764B8 (no) |
| JP (1) | JP2004508284A (no) |
| KR (1) | KR20030036138A (no) |
| CN (1) | CN1400975A (no) |
| AP (1) | AP2002002598A0 (no) |
| AR (1) | AR027437A1 (no) |
| AT (1) | ATE325807T1 (no) |
| AU (1) | AU2001230440A1 (no) |
| BG (1) | BG106906A (no) |
| BR (1) | BR0108408A (no) |
| CA (1) | CA2400619A1 (no) |
| CO (1) | CO5271668A1 (no) |
| CR (1) | CR6722A (no) |
| CZ (1) | CZ20022703A3 (no) |
| DE (1) | DE60119492T2 (no) |
| EA (1) | EA004987B1 (no) |
| EE (1) | EE200200452A (no) |
| ES (1) | ES2260199T3 (no) |
| GB (1) | GB0003960D0 (no) |
| GT (1) | GT200100027A (no) |
| HN (1) | HN2001000027A (no) |
| HR (1) | HRP20020676A2 (no) |
| HU (1) | HUP0301055A2 (no) |
| IL (1) | IL150543A0 (no) |
| IS (1) | IS6458A (no) |
| MA (1) | MA26873A1 (no) |
| MX (1) | MXPA02008068A (no) |
| NO (1) | NO20023894L (no) |
| NZ (1) | NZ519971A (no) |
| OA (1) | OA12177A (no) |
| PA (1) | PA8511801A1 (no) |
| PE (1) | PE20011122A1 (no) |
| PL (1) | PL357220A1 (no) |
| SK (1) | SK11692002A3 (no) |
| SV (1) | SV2002000317A (no) |
| TN (1) | TNSN01028A1 (no) |
| WO (1) | WO2001060835A1 (no) |
| ZA (1) | ZA200206526B (no) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6232297B1 (en) * | 1999-02-01 | 2001-05-15 | University Of Virginia Patent Foundation | Methods and compositions for treating inflammatory response |
| US7378400B2 (en) * | 1999-02-01 | 2008-05-27 | University Of Virginia Patent Foundation | Method to reduce an inflammatory response from arthritis |
| US7427606B2 (en) * | 1999-02-01 | 2008-09-23 | University Of Virginia Patent Foundation | Method to reduce inflammatory response in transplanted tissue |
| GB9913932D0 (en) * | 1999-06-15 | 1999-08-18 | Pfizer Ltd | Purine derivatives |
| US6753322B2 (en) * | 2000-06-06 | 2004-06-22 | Pfizer Inc | 2-aminocarbonyl-9H-purine derivatives |
| US6921753B2 (en) | 2000-06-27 | 2005-07-26 | Pfizer Inc | Purine derivatives |
| GB0022695D0 (en) | 2000-09-15 | 2000-11-01 | Pfizer Ltd | Purine Derivatives |
| JP4514452B2 (ja) * | 2001-10-01 | 2010-07-28 | ユニバーシティ オブ バージニア パテント ファウンデーション | A2aアゴニスト活性を有する2−プロピルアデノシン・アナログおよびその組成物 |
| GB0129270D0 (en) * | 2001-12-06 | 2002-01-23 | Pfizer Ltd | Pharmaceutical combination |
| GB0129273D0 (en) * | 2001-12-06 | 2002-01-23 | Pfizer Ltd | Crystalline drug form |
| GB0129397D0 (en) * | 2001-12-07 | 2002-01-30 | Pfizer Ltd | Pharmaceutical combination |
| US7414036B2 (en) | 2002-01-25 | 2008-08-19 | Muscagen Limited | Compounds useful as A3 adenosine receptor agonists |
| AR044519A1 (es) | 2003-05-02 | 2005-09-14 | Novartis Ag | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina |
| GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
| GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
| EP2221307A1 (en) | 2004-05-26 | 2010-08-25 | Inotek Pharmaceuticals Corporation | Purine derivatives as adenosine A1 receptor agonists and methods of use thereof |
| WO2006015357A2 (en) * | 2004-08-02 | 2006-02-09 | University Of Virginia Patent Foundation | 2-propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity |
| US7576069B2 (en) * | 2004-08-02 | 2009-08-18 | University Of Virginia Patent Foundation | 2-polycyclic propynyl adenosine analogs having A2A agonist activity |
| US7442687B2 (en) * | 2004-08-02 | 2008-10-28 | The University Of Virginia Patent Foundation | 2-polycyclic propynyl adenosine analogs having A2A agonist activity |
| NZ554506A (en) * | 2004-09-20 | 2011-01-28 | Inotek Pharmaceuticals Corp | Purine derivatives and methods of use thereof |
| GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
| GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
| GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
| GB0500785D0 (en) | 2005-01-14 | 2005-02-23 | Novartis Ag | Organic compounds |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| EP1957530A2 (en) | 2005-10-21 | 2008-08-20 | Novartis AG | Human antibodies against il13 and therapeutic uses |
| US7732424B2 (en) * | 2005-11-30 | 2010-06-08 | Inotek Pharmaceuticals Corporation | Purine derivatives and methods of use thereof |
| GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
| US20080027022A1 (en) * | 2006-02-08 | 2008-01-31 | Linden Joel M | Method to treat gastric lesions |
| WO2007120972A2 (en) | 2006-02-10 | 2007-10-25 | University Of Virginia Patent Foundation | Method to treat sickle cell disease |
| PT2013211E (pt) * | 2006-04-21 | 2012-06-21 | Novartis Ag | Derivados de purina para utilização como agonistas de receptores a2a de adenosina |
| GB0607951D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| GB0607950D0 (en) | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| US8188063B2 (en) * | 2006-06-19 | 2012-05-29 | University Of Virginia Patent Foundation | Use of adenosine A2A modulators to treat spinal cord injury |
| EP1889846A1 (en) | 2006-07-13 | 2008-02-20 | Novartis AG | Purine derivatives as A2a agonists |
| EP1903044A1 (en) | 2006-09-14 | 2008-03-26 | Novartis AG | Adenosine Derivatives as A2A Receptor Agonists |
| EP2081933B1 (en) | 2006-09-29 | 2011-03-23 | Novartis AG | Pyrazolopyrimidines as pi3k lipid kinase inhibitors |
| MX2009004715A (es) | 2006-10-30 | 2009-05-20 | Novartis Ag | Compuestos heterociclicos como agentes antiinflamatorios. |
| WO2008133129A1 (ja) * | 2007-04-16 | 2008-11-06 | Santen Pharmaceutical Co., Ltd. | アデノシンa2a受容体アゴニストを有効成分として含有する緑内障治療剤 |
| US8058259B2 (en) * | 2007-12-20 | 2011-11-15 | University Of Virginia Patent Foundation | Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists |
| JP5584138B2 (ja) | 2008-01-11 | 2014-09-03 | ノバルティス アーゲー | キナーゼ阻害剤としてのピリミジン類 |
| UA104010C2 (en) * | 2008-12-18 | 2013-12-25 | Эли Лилли Энд Компани | Purine compounds |
| US20110281917A1 (en) | 2009-01-29 | 2011-11-17 | Darrin Stuart | Substituted Benzimidazoles for the Treatment of Astrocytomas |
| US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
| EA201200260A1 (ru) | 2009-08-12 | 2012-09-28 | Новартис Аг | Гетероциклические гидразоны и их применение для лечения рака и воспаления |
| AU2010284254B2 (en) | 2009-08-17 | 2015-09-17 | Intellikine, Llc | Heterocyclic compounds and uses thereof |
| EA201200318A1 (ru) | 2009-08-20 | 2012-09-28 | Новартис Аг | Гетероциклические оксимы |
| SI2523669T1 (sl) | 2010-01-11 | 2017-05-31 | Inotek Pharmaceuticals Corporation | Kombinacija, komplet in metoda za zmanjšanje intraokularnega tlaka |
| SG184221A1 (en) | 2010-03-26 | 2012-10-30 | Inotek Pharmaceuticals Corp | Method of reducing intraocular pressure in humans using n6 -cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| UY33597A (es) | 2010-09-09 | 2012-04-30 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
| US20130324526A1 (en) | 2011-02-10 | 2013-12-05 | Novartis Ag | [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase |
| WO2012116237A2 (en) | 2011-02-23 | 2012-08-30 | Intellikine, Llc | Heterocyclic compounds and uses thereof |
| AU2012220572A1 (en) | 2011-02-25 | 2013-08-29 | Irm Llc | Compounds and compositions as trk inhibitors |
| EA026655B1 (ru) | 2011-09-15 | 2017-05-31 | Новартис Аг | 6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ |
| JP6130391B2 (ja) | 2011-11-23 | 2017-05-17 | インテリカイン, エルエルシー | Mtor阻害剤を使用する強化された治療レジメン |
| SG11201403979TA (en) | 2012-01-26 | 2014-08-28 | Inotek Pharmaceuticals Corp | Anhydrous polymorphs of (2r,3s,4r,5r)-5-(6-(cyclopentylamino)-9h-purin-9-yl)-3,4-dihydroxytetrahydrofuran-2-yl) } methyl nitrate and processes of preparation thereof |
| US20150297604A1 (en) | 2012-04-03 | 2015-10-22 | Novartis Ag | Combination Products with Tyrosine Kinase Inhibitors and their Use |
| SG11201506882YA (en) | 2013-03-15 | 2015-09-29 | Inotek Pharmaceuticals Corp | Ophthalmic formulations |
| CN105246482A (zh) | 2013-03-15 | 2016-01-13 | 因特利凯有限责任公司 | 激酶抑制剂的组合及其用途 |
| TW201605450A (zh) | 2013-12-03 | 2016-02-16 | 諾華公司 | Mdm2抑制劑與BRAF抑制劑之組合及其用途 |
| WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
| US10940150B2 (en) | 2014-07-28 | 2021-03-09 | Technische Universitaet Dresden | Thymine derivatives and quinazoline-dione derivatives for the inhibition of HSP27 |
| JP6526789B2 (ja) | 2014-07-31 | 2019-06-05 | ノバルティス アーゲー | 組み合わせ療法 |
| TWI771266B (zh) * | 2015-03-13 | 2022-07-11 | 瑞典商杜比國際公司 | 解碼具有增強頻譜帶複製元資料在至少一填充元素中的音訊位元流 |
| CA3102279A1 (en) | 2018-06-01 | 2019-12-05 | Cornell University | Combination therapy for pi3k-associated disease or disorder |
| TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5140015A (en) * | 1990-02-20 | 1992-08-18 | Whitby Research, Inc. | 2-aralkoxy and 2-alkoxy adenosine derivatives as coronary vasodilators and antihypertensive agents |
| US5189027A (en) * | 1990-11-30 | 1993-02-23 | Yamasa Shoyu Kabushiki Kaisha | 2-substituted adenosine derivatives and pharmaceutical compositions for circulatory diseases |
| IT1254915B (it) * | 1992-04-24 | 1995-10-11 | Gloria Cristalli | Derivati di adenosina ad attivita' a2 agonista |
| BR9914526A (pt) * | 1998-10-16 | 2001-07-03 | Pfizer | Derivados de adenina |
| GB9913932D0 (en) | 1999-06-15 | 1999-08-18 | Pfizer Ltd | Purine derivatives |
| GB9924361D0 (en) | 1999-10-14 | 1999-12-15 | Pfizer Ltd | Purine derivatives |
| GB9924363D0 (en) | 1999-10-14 | 1999-12-15 | Pfizer Central Res | Purine derivatives |
-
2000
- 2000-02-18 GB GBGB0003960.2A patent/GB0003960D0/en not_active Ceased
-
2001
- 2001-02-09 BR BR0108408-9A patent/BR0108408A/pt not_active IP Right Cessation
- 2001-02-09 OA OA1200200250A patent/OA12177A/en unknown
- 2001-02-09 NZ NZ519971A patent/NZ519971A/en unknown
- 2001-02-09 AU AU2001230440A patent/AU2001230440A1/en not_active Abandoned
- 2001-02-09 EA EA200200770A patent/EA004987B1/ru not_active IP Right Cessation
- 2001-02-09 CZ CZ20022703A patent/CZ20022703A3/cs unknown
- 2001-02-09 HU HU0301055A patent/HUP0301055A2/hu unknown
- 2001-02-09 CA CA002400619A patent/CA2400619A1/en not_active Abandoned
- 2001-02-09 PL PL01357220A patent/PL357220A1/xx not_active Application Discontinuation
- 2001-02-09 IL IL15054301A patent/IL150543A0/xx unknown
- 2001-02-09 MX MXPA02008068A patent/MXPA02008068A/es active IP Right Grant
- 2001-02-09 WO PCT/IB2001/000167 patent/WO2001060835A1/en not_active Ceased
- 2001-02-09 ES ES01902583T patent/ES2260199T3/es not_active Expired - Lifetime
- 2001-02-09 CN CN01805069A patent/CN1400975A/zh active Pending
- 2001-02-09 KR KR1020027010481A patent/KR20030036138A/ko not_active Abandoned
- 2001-02-09 AT AT01902583T patent/ATE325807T1/de not_active IP Right Cessation
- 2001-02-09 EP EP01902583A patent/EP1255764B8/en not_active Expired - Lifetime
- 2001-02-09 EE EEP200200452A patent/EE200200452A/xx unknown
- 2001-02-09 SK SK1169-2002A patent/SK11692002A3/sk unknown
- 2001-02-09 HR HRP20020676 patent/HRP20020676A2/hr not_active Application Discontinuation
- 2001-02-09 AP APAP/P/2002/002598A patent/AP2002002598A0/en unknown
- 2001-02-09 JP JP2001560219A patent/JP2004508284A/ja active Pending
- 2001-02-09 DE DE60119492T patent/DE60119492T2/de not_active Expired - Fee Related
- 2001-02-12 GT GT200100027A patent/GT200100027A/es unknown
- 2001-02-15 HN HN2001000027A patent/HN2001000027A/es unknown
- 2001-02-15 PA PA20018511801A patent/PA8511801A1/es unknown
- 2001-02-15 AR ARP010100690A patent/AR027437A1/es not_active Application Discontinuation
- 2001-02-15 CO CO01012091A patent/CO5271668A1/es not_active Application Discontinuation
- 2001-02-16 TN TNTNSN01028A patent/TNSN01028A1/fr unknown
- 2001-02-16 SV SV2001000317A patent/SV2002000317A/es not_active Application Discontinuation
- 2001-02-16 PE PE2001000174A patent/PE20011122A1/es not_active Application Discontinuation
- 2001-02-20 US US09/789,236 patent/US6525032B2/en not_active Expired - Fee Related
-
2002
- 2002-07-05 BG BG106906A patent/BG106906A/xx unknown
- 2002-07-05 IS IS6458A patent/IS6458A/is unknown
- 2002-08-06 CR CR6722A patent/CR6722A/es not_active Application Discontinuation
- 2002-08-12 MA MA26771A patent/MA26873A1/fr unknown
- 2002-08-15 ZA ZA200206526A patent/ZA200206526B/en unknown
- 2002-08-16 NO NO20023894A patent/NO20023894L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE325807T1 (de) | Purinderivate | |
| DE60103537D1 (de) | Purinderivate | |
| ATE431356T1 (de) | 2-aminocarbonyl-9h-purinderivative | |
| DE60116260D1 (de) | Antivirale azaindolderivate | |
| ATE321065T1 (de) | Purin-derivate | |
| ATE238336T1 (de) | Purin-derivate | |
| IS6196A (is) | Púrín afleiður | |
| ATE372988T1 (de) | Pyrimidin-derivate | |
| DK1280809T3 (da) | Antitumorecteinascidinderivater | |
| ATE298332T1 (de) | Decahydro-isochinolinderivate | |
| DK1322593T3 (da) | O-substituerede-6-methyl-tramadol-derivater | |
| ATE280752T1 (de) | Aminomethyl-phenyl-cyclohexanonderivate | |
| ATE374776T1 (de) | Pyrrolotriazolopyrimidinonderivate | |
| NO20024393D0 (no) | 2-fenylpyran-4-on-derivater | |
| EP1295891A4 (en) | Nucleoside derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |